Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma
NCT01570166 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210
Last updated 2019-06-26
Summary
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC. Intrahepatic recurrence of HCC after partial hepatectomy is common and was reported to be more than 77% within 5 years after surgery. Repeat hepatectomy is an effective treatment for intrahepatic HCC recurrence, with a 5-year survival rate of 19.4-56%. This is comparable to the survival after initial hepatectomy for HCC. Unfortunately, repeat hepatectomy could be carried out only in a small proportion of patients with HCC recurrence (10.4-31%), either because of the poor functional liver reserve or because of widespread intrahepatic recurrence. In the past two decades, percutaneous radiofrequency ablation (PRFA) has emerged as a new treatment modality and has attracted great interest because of its effectiveness and safety for small HCC (≤ 5.0 cm). Studies using PRFA to treat recurrent HCC after partial hepatectomy reported a 3-year survival rate of 62-68%, which is comparable to those achieved by surgery. PRFA is particularly suitable to treat recurrent HCC after partial hepatectomy because these tumors are usually detected when they are small and PRFA causes the least deterioration of liver function in the patients. To the best of our knowledge, there has been no report published in the medical literature comparing the efficacy of repeat hepatectomy with PRFA for recurrent HCC. The aim of this retrospective study is to compare the outcome of repeat hepatectomy with PRFA for small recurrent HCC after partial hepatectomy.
Conditions
Interventions
- PROCEDURE
-
HR
HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
- PROCEDURE
-
RFA
For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- FACTORIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-11-01
- Primary Completion
- 2019-03-01
- Completion
- 2023-03-01
Countries
- China
Study Locations
More Related Trials
-
Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
NCT01415063 ·Status: UNKNOWN ·Phase: PHASE4
-
Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC
NCT05433701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Radiofrequency Ablation Assisted Hepatectomy Versus Hepatectomy Alone for Advanced Hepatocellular Carcinoma
NCT01713244 ·Status: UNKNOWN ·Phase: NA
-
Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
NCT00557024 ·Status: UNKNOWN ·Phase: PHASE4
-
Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels
NCT00814242 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
NCT07305428 ·Status: RECRUITING ·Phase: NA
-
No-touch RFA Versus Traditional RFA for Small Hepatocellular Carcinoma
NCT02830737 ·Status: UNKNOWN ·Phase: NA
-
Resection+Highly Purified CTL Versus Resection Alone for HCC
NCT02709070 ·Status: UNKNOWN ·Phase: PHASE3
-
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
NCT01850667 ·Status: COMPLETED ·Phase: PHASE2
-
Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus
NCT01600196 ·Status: TERMINATED ·Phase: PHASE4
-
Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma
NCT03988998 ·Status: UNKNOWN ·Phase: PHASE3
-
Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
NCT05057104 ·Status: UNKNOWN
-
Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm
NCT00479050 ·Status: COMPLETED ·Phase: PHASE1
-
Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation
NCT04555265 ·Status: COMPLETED ·Phase: NA
-
The Overall Survival of Patients With Unresectable HCC in Real-life
NCT03612726 ·Status: RECRUITING
-
Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm
NCT01825824 ·Status: UNKNOWN ·Phase: PHASE2
-
Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma
NCT00554905 ·Status: UNKNOWN ·Phase: PHASE4
-
Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)
NCT05277675 ·Status: UNKNOWN ·Phase: NA
-
Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis
NCT02309788 ·Status: UNKNOWN
-
Watch and Wait and Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular Carcinoma
NCT05349331 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Hepatectomy on HCC Recurrence
NCT06390228 ·Status: COMPLETED
-
Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.
NCT03790059 ·Status: UNKNOWN ·Phase: NA
-
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
NCT02187081 ·Status: UNKNOWN ·Phase: NA
-
Ablation Combined With PD-1 in HCC: Phase II Study
NCT04652440 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma
NCT00720668 ·Status: UNKNOWN